Who are PACLITAXEL's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Klisyri, Jevtana Kit, Halaven, Ixempra Kit, Taxotere, DOCETAXEL.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chembl-chembl428647.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

PACLITAXEL — Competitive Intelligence Brief

PACLITAXEL (PACLITAXEL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microtubule Inhibitor [EPC].

marketed Microtubule Inhibitor [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

PACLITAXEL (PACLITAXEL).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PACLITAXEL TARGET	PACLITAXEL		marketed	Microtubule Inhibitor [EPC]		1992-01-01
Klisyri	TIRBANIBULIN	Almirall	marketed	Microtubule Inhibitor [EPC]	Tyrosine-protein kinase Lyn	2020-01-01
Jevtana Kit	cabazitaxel	Accord Hlthcare	marketed	Microtubule Inhibitor	Tubulin beta	2010-01-01
Halaven	ERIBULIN	Eisai	marketed	Microtubule Inhibitor	Tubulin beta	2010-01-01
Ixempra Kit	IXABEPILONE	R-Pharm Us Llc	marketed	Microtubule Inhibitor	Apoptosis regulator Bcl-2	2007-01-01
Taxotere	Docetaxel	Sanofi	marketed	Microtubule Inhibitor [EPC]	Growth hormone-releasing hormone receptor	1996-01-01
DOCETAXEL	DOCETAXEL		marketed	Microtubule Inhibitor [EPC]		1995-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-06-10 — Jevtana Kit · 7241907*PED · Compound · US
2030-10-27 — Jevtana Kit · 10716777 · Method of Use · US
2030-10-27 — Jevtana Kit · 8927592 · Method of Use · US
2030-10-27 — Jevtana Kit · 12453712 · Method of Use · US
2030-10-27 — Jevtana Kit · 10583110 · Method of Use · US
2031-04-27 — Jevtana Kit · 12453712*PED · Compound · US
2031-04-27 — Jevtana Kit · 8927592*PED · Compound · US
2031-04-27 — Jevtana Kit · 10583110*PED · Compound · US
2031-04-27 — Jevtana Kit · 10716777*PED · Compound · US
2031-08-07 — Taxotere · 10842770 · Formulation · US
2033-09-30 — Taxotere · 9308195 · Formulation · US
2033-09-30 — Taxotere · 9763880 · Method of Use · US
2033-09-30 — Taxotere · 8940786 · Formulation · US
2036-03-14 — Taxotere · 10398785 · Formulation · US
2036-05-16 — Taxotere · 12090135 · Formulation · US
2036-05-16 — Taxotere · 11419842 · Formulation · US
2036-05-16 — Taxotere · 12090134 · Formulation · US

Sponsor landscape (Microtubule Inhibitor [EPC] class)

· 2 drugs in this class
Almirall · 1 drug in this class
Pfizer · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PACLITAXEL — Competitive Intelligence Brief. https://druglandscape.com/ci/chembl-chembl428647. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab